RSS

turoctocog alfa

The latest interim data from the guardian2 extension trial for Novo Nordisk NovoEight showed that in a phase 3 trial, long-term efficacy and safety in the prophylaxis and treatment of bleeds was achieved in people with severe haemophilia A. more

News